{"id":22145,"date":"2017-11-14T01:03:13","date_gmt":"2017-11-14T06:03:13","guid":{"rendered":"https:\/\/digital.hbs.edu\/platform-rctom\/submission\/digitalizing-drug-development\/"},"modified":"2017-11-14T01:03:13","modified_gmt":"2017-11-14T06:03:13","slug":"digitalizing-drug-development","status":"publish","type":"hck-submission","link":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/","title":{"rendered":"Digitalizing Drug Development"},"content":{"rendered":"

As debates about health insurance reform rumble and patient care models shift from fee-for-service to fee-for-value, another revolution is sweeping the healthcare industry:\u00a0 pharmaceutical supply chain digitalization.\u00a0 For executives at Pfizer, the world\u2019s 3rd<\/sup> largest pharmaceutical company, this megatrend cannot be ignored.<\/p>\n

A third of the pharmaceutical industry\u2019s profit and loss is attributable to the supply chain.[1]<\/a>\u00a0 Pfizer\u2019s supply chain is particularly complex, spanning 66 manufacturing sites, 200+ supply partners, and 134 logistics centers across 175+ markets.[2]<\/a>\u00a0 This network has only grown more complex with Pfizer\u2019s recent acquisition of Hospira, adding 13 new manufacturing sites.[3]<\/a>\u00a0 Increasing visibility and efficiency across Pfizer\u2019s supply chain has never been more urgent.<\/p>\n

Enter Digitalization<\/strong><\/p>\n

Whether digitalization concerns or excites Pfizer\u2019s management will depend on whether they can capture its many benefits before their competitors do.\u00a0 Digitalization can increase Pfizer\u2019s inventory turnover.\u00a0 Currently, Pfizer\u2019s days-sales-in-inventory soars above 200, while peer companies Johnson & Johnson, Novartis, and Merck maintain ratios in the 130s.[4]<\/a>\u00a0 Embedding track-and-trace technology can improve Pfizer\u2019s forecasting and capture some of the $25 billion tied up in wasted inventory across the pharmaceutical industry.[5]<\/a>\u00a0 Digitalization can also reduce plant downtime.\u00a0 While downtime is notoriously high across the pharmaceutical industry, machine-to-machine communication and machine learning can reduce it by 30-40%.[6]<\/a>\u00a0 Embedding sensors throughout the supply chain can provide Pfizer\u2019s managers with real-time insights to adjust batch sizes, mitigate product obsolescence, avoid stockouts, and improve customer retention.[7]<\/a>\u00a0 Sensors can also improve quality by allowing Pfizer to monitor equipment as chemicals are mixed and pills are pressed.[8]<\/a>\u00a0 Lastly, digitalization will be necessary for regulatory compliance, since the Drug Supply Chain Security Act (2013) will soon require Pfizer to implement product serialization across its supply chain.[9]<\/a><\/p>\n

The race towards pharmaceutical supply chain digitalization has already begun.\u00a0 Merck is implementing sensors and intelligent software to better understand how products are performing in the market and to help accelerate their planning processes.[10]<\/a>\u00a0 Cipla improved their production forecasting by implementing new supply chain planning software\u2014an investment that paid for itself in six months.[11]<\/a>\u00a0 Cipla is also planning to use artificial intelligence to create a \u201cdriverless\u201d supply chain.[12]<\/a>\u00a0 Other companies are using infrared technology to detect counterfeit medicines more efficiently.[13]<\/a><\/p>\n

Early Progress<\/strong><\/p>\n

Pfizer\u2019s management is taking several steps to respond to this megatrend.\u00a0 In the short-term, Pfizer has installed temperature monitoring and cooling technologies to accommodate its growing portfolio of temperature-dependent drugs.[14]<\/a>\u00a0 Pfizer has also been implementing a cloud-based supplier system with track-and-trace capabilities across 500 different partners.[15]<\/a>\u00a0 This will bring all partners onto the same interoperable platform so that Pfizer can gather information and map products as they move through their network.<\/p>\n

Over the longer-term, Pfizer envisions full end-to-end visibility that extends all the way to the patient.\u00a0 To that end, Pfizer has launched a partnership with IBM aimed at using wearable technology to monitor and analyze data from patients with Parkinson\u2019s disease.\u00a0 By understanding the frequency and severity of various symptoms as they arise, Pfizer hopes to expedite clinical trials and uncover new effective drugs.[16]<\/a>\u00a0 This early foray into the Internet-of-Things (IOT) is likely only the beginning.<\/p>\n

Next Steps<\/strong><\/p>\n

Beyond these actions, Pfizer can take several additional steps to ride the digitalization wave.\u00a0 In the short-term, mindset shifts are critical to embracing digitalization.\u00a0 According to pharma experts, a major impediment to supply chain digitalization is employees\u2019 reluctance to \u201cchange how they\u2019ve always done things.\u201d[17]<\/a>\u00a0 This underscores the need for Pfizer\u2019s management to communicate a compelling digitalization vision.\u00a0 Meanwhile, Pfizer\u2019s leaders should pick 1-2 new digitalization projects that the company can get started on immediately,[18]<\/a> with the goal of achieving quick wins and diffusing skepticism.<\/p>\n

Over the longer-term, Pfizer should expand its IOT investments into other therapeutic areas where real-time patient data could speed up the drug development and delivery process.\u00a0 Through cost-benefit analysis, they should determine whether to replace or retrofit plant machinery with new IOT-equipped technologies. \u00a0Pfizer already expects to invest $1.9 billion in PPE in 2017 alone, on top of $2.6 billion spent over the previous two years.[19]<\/a>\u00a0 Relative to these large investments and to Pfizer\u2019s $13 billion in total PPE, plant retrofits are unlikely to stretch capital budgets\u2014particularly with the decreasing cost of IOT sensors.[20]<\/a>\u00a0 Lastly, Pfizer\u2019s physical capital investments should be matched with human capital investments.\u00a0 Merck, by comparison, is recruiting younger employees and training older ones in order to build the skillsets needed to implement new technological solutions.[21]<\/a>\u00a0 Pfizer should likewise diversify its talent so that its workforce is ready for digitalization.<\/p>\n

Conclusion<\/strong><\/p>\n

Opportunities for supply chain digitalization at Pfizer abound.\u00a0 Nonetheless, questions remain.\u00a0 Digitalization is increasingly used to forecast demand\u2014but how far downstream to the point-of-sale should Pfizer\u2019s digital network extend before it compromises patient confidentiality?\u00a0 And digitalization requires the cooperation of hundreds of players across the supply chain\u2014but will partners have an incentive to share increasing amounts of data?<\/p>\n

(800 words)<\/p>\n

[1]<\/a> Edwin Lopez, \u201cWhy Merck & Co. turned to supply chain integration to save costs,\u201d Supply Chain Dive, March 3, 2017, https:\/\/www.supplychaindive.com\/news\/merck-co-supply-demand-planning-manufacturing-integration\/436496\/<\/a>, accessed November 2017.<\/p>\n

[2]<\/a> Pfizer, \u201c2015 Annual Review: Manufacturing and Supply Chain,\u201d 2015, https:\/\/www.pfizer.com\/files\/investors\/financial_reports\/annual_reports\/2015\/manufacturing-and-supply-chain.htm<\/a>, accessed November 2017.<\/p>\n

[3]<\/a> Pfizer, \u201c2015 Annual Review: Manufacturing and Supply Chain,\u201d 2015, https:\/\/www.pfizer.com\/files\/investors\/financial_reports\/annual_reports\/2015\/manufacturing-and-supply-chain.htm<\/a>, accessed November 2017.<\/p>\n

[4]<\/a> Stock Analysis on Net, \u201cPfizer: Short-Term (Operating) Activity Analysis,\u201d December, 31, 2016, https:\/\/www.stock-analysis-on.net\/NYSE\/Company\/Pfizer-Inc\/Ratios\/Short-term-Operating-Activity<\/a>, accessed November 2017.<\/p>\n

[5]<\/a> David Keeling, Martin Losch, Ulf Schrader, \u201cOutlook on pharma operations,\u201d McKinsey & Company, 2010, https:\/\/www.mckinsey.com\/~\/media\/mckinsey\/dotcom\/client_service\/operations\/pdfs\/outlook_on_pharma_operations.ashx<\/a>, accessed November 2017.<\/p>\n

[6]<\/a> Dr. Marcus Ehrhardt, Peter Behner, \u201cDigitization in pharma: Gaining an edge in operations,\u201d Strategy&, October 19, 2016, https:\/\/www.strategyand.pwc.com\/reports\/digitization-in-pharma<\/a>, accessed November 2017.<\/p>\n

[7]<\/a> Joseph Ludorf, \u201cImprove your supply chain forecasting,\u201d IndustryWeek, October 26, 2012, http:\/\/www.industryweek.com\/planning-amp-forecasting\/improve-your-supply-chain-forecasting<\/a>, accessed November 2017.<\/p>\n

[8]<\/a> Brian Hartmann, William P. King, Subu Narayanan, \u201cDigital manufacturing: The revolution will be virtualized,\u201d McKinsey & Company, August 2015, https:\/\/www.mckinsey.com\/business-functions\/operations\/our-insights\/digital-manufacturing-the-revolution-will-be-virtualized<\/a>, accessed November 2017.<\/p>\n

[9]<\/a> Food and Drug Administration, \u201cDrug Supply Chain Security Act: Overview of Product Tracing Requirements,\u201d September 2015, https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/DrugIntegrityandSupplyChainSecurity\/DrugSupplyChainSecurityAct\/UCM464907.pdf<\/a>, accessed November 2017.<\/p>\n

[10]<\/a> Hans Thalbauer, Michael S. Goldberg, \u201cAmp The Supply Chain,\u201d Digitalist Magazine, May 10, 2017, http:\/\/www.digitalistmag.com\/digital-supply-networks\/2017\/05\/10\/amp-the-supply-chain-05034986<\/a>, accessed November 2017.<\/p>\n

[11]<\/a> Joseph Ludorf, \u201cImprove your supply chain forecasting,\u201d IndustryWeek, October 26, 2012, http:\/\/www.industryweek.com\/planning-amp-forecasting\/improve-your-supply-chain-forecasting<\/a>, accessed November 2017.<\/p>\n

[12]<\/a> Gary Forger, \u201cNextGen Supply Chain: The new look of supply chain automation,\u201d Supply Chain Management Review, September 26, 2017, http:\/\/www.scmr.com\/article\/nextgen_supply_chain_the_new_look_of_supply_chain_automation<\/a>, accessed November 2017.<\/p>\n

[13]<\/a> Brian Hartmann, William P. King, Subu Narayanan, \u201cDigital manufacturing: The revolution will be virtualized,\u201d McKinsey & Company, August 2015, https:\/\/www.mckinsey.com\/business-functions\/operations\/our-insights\/digital-manufacturing-the-revolution-will-be-virtualized<\/a>, accessed November 2017.<\/p>\n

[14]<\/a> \u201cDigitizing the supply chain: Why Pfizer is investing in IoT, drones and personalized medicine,\u201d Internet of Business, January 31, 2017, https:\/\/internetofbusiness.com\/digitizing-supply-chain-pfizer-iot\/<\/a>, accessed November 2017.<\/p>\n

[15]<\/a> \u201cPfizer moves supply chain to cloud,\u201d Financial Times, 2012, https:\/\/www.ft.com\/content\/1608e5d6-fc59-11e1-ac0f-00144feabdc0<\/a>, accessed November 2017.<\/p>\n

[16]<\/a> Jessica Davis, \u201cIBM, Pfizer partner on experimental Internet of Things study for Parkinson’s Disease care,\u201d Healthcare IT News, April 8, 2016, http:\/\/www.healthcareitnews.com\/news\/ibm-pfizer-partner-experimental-internet-things-study-parkinsons-disease-care<\/a>, accessed November 2017.<\/p>\n

[17]<\/a> Julian Upton, \u201cSetting Sights on the Smart Supply Chain,\u201d Pharmaceutical Executive, Volume 37, Issue 3, March 14, 2017, http:\/\/www.pharmexec.com\/setting-sights-smart-supply-chain<\/a>, accessed November 2017.<\/p>\n

[18]<\/a> World Economic Forum, \u201cIndustrial Internet of Things: Unleashing the Potential of Connected Products and Services,\u201d http:\/\/reports.weforum.org\/industrial-internet-of-things\/5-recommended-actions-for-stakeholders\/<\/a>, accessed November 2017.<\/p>\n

[19]<\/a> Pfizer, \u201c2015 Annual Review: Manufacturing and Supply Chain,\u201d 2015, https:\/\/www.pfizer.com\/files\/investors\/financial_reports\/annual_reports\/2015\/manufacturing-and-supply-chain.htm<\/a>, accessed November 2017.<\/p>\n

[20]<\/a> Mario Honrubia, \u201cIndustrial IoT is booming thanks to a drop in Sensor Prices,\u201d Ennomotive, August 17, 2017, https:\/\/www.ennomotive.com\/industrial-iot-sensor-prices\/<\/a>, accessed November 2017.<\/p>\n

[21]<\/a> Julian Upton, \u201cSetting Sights on the Smart Supply Chain,\u201d Pharmaceutical Executive, Volume 37, Issue 3, March 14, 2017, http:\/\/www.pharmexec.com\/setting-sights-smart-supply-chain<\/a>, accessed November 2017.<\/p>\n","protected":false},"excerpt":{"rendered":"

Pfizer is using digitalization to increase visibility and efficiency across its supply chain.\u00a0 But can the pharmaceutical giant capitalize on these benefits quickly enough?<\/p>\n","protected":false},"author":10049,"featured_media":22146,"comment_status":"open","ping_status":"closed","template":"","categories":[3235,2123,222],"class_list":["post-22145","hck-submission","type-hck-submission","status-publish","has-post-thumbnail","hentry","category-digital-supply-chain","category-digitalization","category-pharmaceuticals","hck-taxonomy-organization-pfizer","hck-taxonomy-industry-pharmaceutical","hck-taxonomy-country-united-states"],"connected_submission_link":"https:\/\/d3.harvard.edu\/platform-rctom\/assignment\/rc-tom-challenge-2017\/","yoast_head":"\nDigitalizing Drug Development - Technology and Operations Management<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Digitalizing Drug Development - Technology and Operations Management\" \/>\n<meta property=\"og:description\" content=\"Pfizer is using digitalization to increase visibility and efficiency across its supply chain.\u00a0 But can the pharmaceutical giant capitalize on these benefits quickly enough?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Technology and Operations Management\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2017\/11\/Digital-Pharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"483\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/\",\"name\":\"Digitalizing Drug Development - Technology and Operations Management\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2017\\\/11\\\/Digital-Pharma.jpg\",\"datePublished\":\"2017-11-14T06:03:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2017\\\/11\\\/Digital-Pharma.jpg\",\"contentUrl\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2017\\\/11\\\/Digital-Pharma.jpg\",\"width\":724,\"height\":483},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/digitalizing-drug-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Submissions\",\"item\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Digitalizing Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/#website\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/\",\"name\":\"Technology and Operations Management\",\"description\":\"MBA Student Perspectives\",\"potentialAction\":[{\"@type\":\"性视界Action\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Digitalizing Drug Development - Technology and Operations Management","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/","og_locale":"en_US","og_type":"article","og_title":"Digitalizing Drug Development - Technology and Operations Management","og_description":"Pfizer is using digitalization to increase visibility and efficiency across its supply chain.\u00a0 But can the pharmaceutical giant capitalize on these benefits quickly enough?","og_url":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/","og_site_name":"Technology and Operations Management","og_image":[{"width":724,"height":483,"url":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2017\/11\/Digital-Pharma.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/","url":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/","name":"Digitalizing Drug Development - Technology and Operations Management","isPartOf":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/#primaryimage"},"image":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2017\/11\/Digital-Pharma.jpg","datePublished":"2017-11-14T06:03:13+00:00","breadcrumb":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/#primaryimage","url":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2017\/11\/Digital-Pharma.jpg","contentUrl":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2017\/11\/Digital-Pharma.jpg","width":724,"height":483},{"@type":"BreadcrumbList","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/digitalizing-drug-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3.harvard.edu\/platform-rctom\/"},{"@type":"ListItem","position":2,"name":"Submissions","item":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/"},{"@type":"ListItem","position":3,"name":"Digitalizing Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/#website","url":"https:\/\/d3.harvard.edu\/platform-rctom\/","name":"Technology and Operations Management","description":"MBA Student Perspectives","potentialAction":[{"@type":"性视界Action","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3.harvard.edu\/platform-rctom\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission\/22145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission"}],"about":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/types\/hck-submission"}],"author":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/users\/10049"}],"replies":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/comments?post=22145"}],"version-history":[{"count":0,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission\/22145\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/media\/22146"}],"wp:attachment":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/media?parent=22145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/categories?post=22145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}